Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2009 Results
Date:11/2/2009

ly safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund its commercial and research and development activities; Vanda's failure to identify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
3. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
4. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
5. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
6. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
7. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
8. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
9. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
10. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
11. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... NH As the federal government plans its exit strategy ... to rethink its role in providing health care to veterans, ... of Medicine . , "To simply go on doing more ... that the Veterans Health Administration,s cost and population structure pose ... Institute for Health Policy & Clinical Practice, and David Auerbach, ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , ... record by walking 5,000 miles in a single year without ... the thousands of individual stories of TrekDesk treadmill desk users ... more than the others. , Kirklyn has launched a website ... a range of 54,823 steps (presumably on an off day) ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medical,Equipment, Inc. (Pink Sheets: SHMM) announced today that ... completed its seventh,staffing agreement and is aggressively filling ... CEO of parent company Southern Home Medical,stated, "This ... has far,exceeded their own expectations in their second ...
... June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced ... candidate in its Beta-catenin Pathway Inhibitor program. This novel compound ... cancer cell death. The Company plans to begin ... is one of the most commonly activated cancer pathways and ...
... Pryor, CEO of Portico,Learning Solutions (Portico), a provider ... Portico,s partnership with FOX,Networks Group (FNG), the umbrella ... Networks, FOX Reality, and the National Geographic,Channel., ... News Corporation businesses,FNG launched a massive effort to ...
... Mandate is Quick to Implement, ROCKLIN, Calif., ... a provider of relay and wireless communications and,professional ... AT&T today announced they would become the,first companies ... a,10-digit numbering system described in the FCC ruling ...
... The International Association for Dental Research (IADR) is presenting ... Lecturer in Periodontology at the School of Dental Sciences ... will be presented at the IADR 86th General Session ... Dr. Preshaw holds a B.D.S. from Newcastle University, a ...
... Va. The International Association for Dental Research ... Diagnostic Sciences (Emeritus) at the School of Dental ... Buffalo, as the 2008,recipient of the Pharmacology/Therapeutics/Toxicology Research ... IADR 86th,General Session & Exhibition in Toronto, ON, ...
Cached Medicine News:Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:FOX Networks Group in Partnership with Portico Learning Solutions Launches Online Employee Health and Safety Orientation Course for Over 3,300 Employees 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5Health News:Fischman receives Pharmacology/Therapeutics/Toxicology Research Award 2
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Aug. 28, 2014 Tianyin Pharmaceutical Co., ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today updates the timeline for ... (QLF). The Company is scheduled ... for China Food & Drug Administration,s (CFDA) review ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training ... published a case study highlighting one manager,s ... . In September and October 2014, Academy Leadership affiliates ... Albuquerque , Indianapolis , Salt Lake City ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...
... to be Presented at the Upcoming ECCMID Conference, ... the,press release published on 9 April, Arpida Ltd. ... the clinical programme with,intravenous iclaprim in complicated Skin ... has been presented at last year,s ICAAC,and IDSA ...
Cached Medicine Technology:Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3Arpida Provides Further Comments on the Pivotal Phase III Trials 2Arpida Provides Further Comments on the Pivotal Phase III Trials 3Arpida Provides Further Comments on the Pivotal Phase III Trials 4
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: